02
Oct 2018
New drug may boost pancreatic cancer survival rates by 50 per cent
A new treatment that inhibits pancreatic cancer from developing resistance to treatments has shown that it may be a significant breakthrough in the fight against the disease.
Pancreatic cancer is the third deadliest cancer type mainly due to the fact that it is often diagnosed too late and chemotherapy also becomes ineffective in fighting the tumours.
Many patients are not diagnosed until the third or fourth stage of the disease, due to the location of the pancreas within the body, which makes it difficult to detect symptoms before tumours have spread throughout other parts of the body.
Early tests on mice have shown that this new drug, metavert, could stop the cancer from becoming invulnerable and make other treatment drugs more effective, thereby possibly raising survival rates by as much as 50 per cent.
During the tests, the team discovered that the drug not only stopped resistance to chemotherapy, but it also seemed to increase the effectiveness of both chemotherapy and radiation treatments, improving survival rates by as much as 50 per cent in the mice.
Chadwick Lawrence’s specialist team of clinical negligence lawyers have years of experience in medical negligence compensation claims, and have obtained substantial compensation for our clients. Not only do we represent clients in Yorkshire, but because of our reputation we also represent clients nationally.
If you believe that you or a relative may have been injured as a result of clinical/medical negligence, please call for free legal advice from our medical negligence solicitors on the freephone number below.
Posted by Tony May, Partner/head of Clinical Negligence Department, Chadwick Lawrence LLP (tonymay@chadlaw.co.uk ), medical negligence lawyers and clinical negligence solicitors in Huddersfield, Leeds, Wakefield and Halifax, West Yorkshire.
Freephone : 0800 304 738
- Like this ? Share with friends